BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24571737)

  • 1. Targeting kallikrein-related peptidases in prostate cancer.
    Mavridis K; Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2014 Apr; 18(4):365-83. PubMed ID: 24571737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
    Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.
    Cereda V; Formica V; Menghi A; Pellicori S; Roselli M
    Expert Opin Investig Drugs; 2015; 24(7):929-47. PubMed ID: 25858813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the kallikrein-related peptidases for drug development.
    Sotiropoulou G; Pampalakis G
    Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.
    Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA
    Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies.
    Prassas I; Paliouras M; Datti A; Diamandis EP
    Clin Cancer Res; 2008 Sep; 14(18):5778-84. PubMed ID: 18794087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the extended substrate specificity of kallikrein 1-related peptidases.
    Borgoño CA; Gavigan JA; Alves J; Bowles B; Harris JL; Sotiropoulou G; Diamandis EP
    Biol Chem; 2007 Nov; 388(11):1215-25. PubMed ID: 17976015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.
    Avgeris M; Mavridis K; Scorilas A
    Biol Chem; 2012 Apr; 393(5):301-17. PubMed ID: 22505514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
    Scorilas A; Mavridis K
    Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies.
    Dorn J; Bayani J; Yousef GM; Yang F; Magdolen V; Kiechle M; Diamandis EP; Schmitt M
    Thromb Haemost; 2013 Sep; 110(3):408-22. PubMed ID: 23765253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.
    Lovell S; Zhang L; Kryza T; Neodo A; Bock N; De Vita E; Williams ED; Engelsberger E; Xu C; Bakker AT; Maneiro M; Tanaka RJ; Bevan CL; Clements JA; Tate EW
    J Am Chem Soc; 2021 Jun; 143(23):8911-8924. PubMed ID: 34085829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.
    Mavridis K; Scorilas A
    Future Oncol; 2010 Feb; 6(2):269-85. PubMed ID: 20146586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kallikrein-related peptidases in cancers of gastrointestinal tract: an inside view of their role and clinical significance.
    Linardoutsos D; Gazouli M; Machairas A; Bramis I; Zografos GC
    J BUON; 2014; 19(1):53-9. PubMed ID: 24659643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
    Figueroa CD; Molina L; Bhoola KD; Ehrenfeld P
    Biol Chem; 2018 Sep; 399(9):937-957. PubMed ID: 29885274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.
    Kaushal A; Myers SA; Dong Y; Lai J; Tan OL; Bui LT; Hunt ML; Digby MR; Samaratunga H; Gardiner RA; Clements JA; Hooper JD
    Prostate; 2008 Mar; 68(4):381-99. PubMed ID: 18196551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human kallikrein-related peptidase 12: antibody generation and immunohistochemical localization in prostatic tissues.
    Memari N; Diamandis EP; Earle T; Campbell A; Van Dekken H; Van der Kwast TH
    Prostate; 2007 Sep; 67(13):1465-74. PubMed ID: 17654496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer.
    Fuhrman-Luck RA; Silva ML; Dong Y; Irving-Rodgers H; Stoll T; Hastie ML; Loessner D; Gorman JJ; Clements JA
    Proteomics Clin Appl; 2014 Jun; 8(5-6):403-15. PubMed ID: 24535680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
    Pampalakis G; Sotiropoulou G
    Biochim Biophys Acta; 2007 Sep; 1776(1):22-31. PubMed ID: 17629406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolutionary history of tissue kallikreins.
    Pavlopoulou A; Pampalakis G; Michalopoulos I; Sotiropoulou G
    PLoS One; 2010 Nov; 5(11):e13781. PubMed ID: 21072173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.
    Yoon H; Blaber SI; Evans DM; Trim J; Juliano MA; Scarisbrick IA; Blaber M
    Protein Sci; 2008 Nov; 17(11):1998-2007. PubMed ID: 18697857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.